Eculizumab

Drug Profile

Eculizumab

Alternative Names: 5G1-1; 5G1.1; Anti-C5 monoclonal antibody 5G1-1; h5G1.1; Monoclonal antibody 5G1-1; Soliris

Latest Information Update: 22 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alexion Pharmaceuticals
  • Developer Alexion Pharmaceuticals; Brigham and Womens Hospital; Chiba University; Handok Inc
  • Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Delayed graft function; Neuromyelitis optica; Transplant rejection; Haemolytic uraemic syndrome; Myasthenia gravis; Dermatomyositis; Membranous glomerulonephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Registered Myasthenia gravis
  • Phase III Delayed graft function; Neuromyelitis optica
  • Phase II Guillain-Barre syndrome; Renal transplant rejection
  • Preclinical Heart transplant rejection
  • No development reported Antiphospholipid syndrome
  • Discontinued Adult respiratory distress syndrome; Age-related macular degeneration; Allergic asthma; Autoimmune haemolytic anaemia; Bullous pemphigoid; Dermatomyositis; Glomerulonephritis; Immune thrombocytopenic purpura; Lupus nephritis; Membranous glomerulonephritis; Motor neuron disease; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 21 Aug 2017 Registered for Myasthenia gravis (Treatment-experienced) in European Union (IV)
  • 15 Aug 2017 Alexion Pharmaceuticals has patent protection for eculizumab in USA
  • 15 Aug 2017 Alexion Pharmaceuticals has patents pending for eculizumab for Paroxysmal nocturnal haemoglobinuria in Europe and Japan, as well as applications for additional indications such as Myasthenia gravis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top